Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.769 [Categoria DeCS]
Referências encontradas : 73 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8 ir para página                    

  1 / 73 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24603519
[Au] Autor:Kot M; Bogaczewicz J; Krecisz B; Wozniacka A
[Ad] Endereço:From the *Department of Dermatology and Venereology, Medical University of Lodz; and †Department of Occupational Diseases, Nofer Institute of Occupational Medicine, Lodz, Poland.
[Ti] Título:Contact hypersensitivity to haptens of the European standard series and corticosteroid series in the population of adolescents and adults with atopic dermatitis.
[So] Source:Dermatitis;25(2):72-6, 2014 Mar-Apr.
[Is] ISSN:2162-5220
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Until recently, it was thought that in patients with atopic dermatitis (AD), contact hypersensitivity phenomenon occurs less frequently than in the general population because of the impaired cellular immune response. OBJECTIVE: The aim of this study was to evaluate the incidence of contact dermatitis in the population of patients with AD. METHODS: A total of 39 patients with clinical diagnosis of AD during remission were patch tested with 28 European Baseline Series allergens and 8 corticosteroids allergens in different concentrations and media. Twenty-nine (74.3%) patients were female and 10 (25.6%) patients were male. Thirty-three (84.6%) patients were older than 18 years. The mean duration of AD was 20 years. RESULTS: Nineteen (48%) patients had an allergic reaction to at least 1 European Standard Series allergen, and 5 (12.8%) patients had an allergic reaction to at least 1 corticosteroid. The most common allergens giving positive results were nickel sulfate (28.2%), potassium dichromate (20.5%), cobalt chloride (12.8%), and phenylenediamine, budesonide, betamethasone, clobetasol, and dexamethasone (7.7% each). CONCLUSIONS: This study shows that allergic contact hypersensitivity is common among patients with AD and affects up to 40% of cases. Contact allergy to corticosteroids becomes a serious problem in the treatment of chronic inflammatory dermatoses such as AD.
[Mh] Termos MeSH primário: Corticosteroides/efeitos adversos
Anti-Inflamatórios/efeitos adversos
Dermatite Alérgica de Contato/etiologia
Dermatite Atópica/imunologia
Haptenos/efeitos adversos
Pregnadienotrióis/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Budesonida/efeitos adversos
Cobalto/efeitos adversos
Feminino
Seres Humanos
Masculino
Meia-Idade
Níquel/efeitos adversos
Testes do Emplastro
Fenilenodiaminas/efeitos adversos
Dicromato de Potássio/efeitos adversos
Fatores Sexuais
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents); 0 (Haptens); 0 (Phenylenediamines); 0 (Pregnadienetriols); 3G0H8C9362 (Cobalt); 4FLT4T3WUN (nickel sulfate); 51333-22-3 (Budesonide); 7OV03QG267 (Nickel); EVS87XF13W (cobaltous chloride); T4423S18FM (Potassium Dichromate)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140308
[St] Status:MEDLINE
[do] DOI:10.1097/DER.0000000000000026


  2 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24292309
[Au] Autor:Khondker L; Khan SI
[Ad] Endereço:Dr Lubna Khondker, Assistant Professor, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka, Bangladesh.
[Ti] Título:Efficacy of levamisole for the treatment of slow spreading vitiligo.
[So] Source:Mymensingh Med J;22(4):761-6, 2013 Oct.
[Is] ISSN:1022-4742
[Cp] País de publicação:Bangladesh
[La] Idioma:eng
[Ab] Resumo:Levamisole can be used as an immunomodifier for an effective treatment of vitiligo. A clinical trial was done to assess the efficacy of levamisole in patients of vitiligo. The study was conducted in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from January 2010 to July 2011. A total number of sixty patients were assigned purposively. Among them thirty patients were belonged to Group A, treated with levamisole alone and another thirty patients belonged to Group B, treated with levamisole 160 mg weekly with topical 0.1% fluocinolone acetonide acetate on the lesions once a day for a duration of 6 months. Patients were followed up every 2 weeks interval and were continued up to 6 weeks. Out of all patients from group A, the mean sizes of the lesions were 8.17cm before treatment but 5.90cm, 4.32cm, and 3.57cm at 1st visit, 2nd visit and 3rd visit respectively after treatment. In Group B, the mean sizes of the lesions were 7.50cm before treatment but 4.92cm, 3.00cm, and 4.75cm at 1st visit, 2nd visit and 3rd visit respectively after treatment. Among the respondents of Group A & B, 25(83.3%) and 27(90%) were cured respectively. This study observed that Levamisol with topical 0.1% fluocinolone was more responsive in percentage but the difference was not statistically significant.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/uso terapêutico
Levamisol/uso terapêutico
Vitiligo/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Feminino
Seres Humanos
Masculino
Meia-Idade
Pregnadienotrióis/administração & dosagem
Vitiligo/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Pregnadienetriols); 2880D3468G (Levamisole); 3693-39-8 (flucloronide)
[Em] Mês de entrada:1404
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131203
[St] Status:MEDLINE


  3 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22428627
[Au] Autor:Salem W; Fraser-Bell S; Gillies M
[Ad] Endereço:Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia. wsal7464@uni.sydney.edu.au
[Ti] Título:Clinical development of new treatments for diabetic macular oedema.
[So] Source:Clin Exp Optom;95(3):297-305, 2012 May.
[Is] ISSN:1444-0938
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:The benchmark treatment for diabetic macular oedema, the major cause of visual impairment in patients with diabetes mellitus, has traditionally been laser photocoagulation; however, as laser treatment does not always improve vision or even prevent further loss in many cases, several new pharmacotherapies that are injected into the vitreous for diabetic macular oedema have been successfully trialled over the past decade. Others are currently being evaluated. The two major classes of these drugs are steroids and vascular endothelial growth factor antagonists. In this article we briefly review the major clinical studies recently conducted in this field.
[Mh] Termos MeSH primário: Retinopatia Diabética/terapia
Edema Macular/terapia
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/uso terapêutico
Aptâmeros de Nucleotídeos/uso terapêutico
Bevacizumab
Extração de Catarata
Dexametasona/administração & dosagem
Seres Humanos
Fotocoagulação a Laser
Pregnadienotrióis/uso terapêutico
Tomografia de Coerência Óptica
Triancinolona Acetonida/efeitos adversos
Triancinolona Acetonida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Aptamers, Nucleotide); 0 (Pregnadienetriols); 2H1PA8H1EN (pegaptanib); 2S9ZZM9Q9V (Bevacizumab); 3693-39-8 (flucloronide); 7S5I7G3JQL (Dexamethasone); F446C597KA (Triamcinolone Acetonide)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120321
[St] Status:MEDLINE
[do] DOI:10.1111/j.1444-0938.2012.00723.x


  4 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21627530
[Au] Autor:Rankin AJ; Khrone SG; Stiles J
[Ad] Endereço:Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA. arankin@vet.k-state.edu
[Ti] Título:Evaluation of four drugs for inhibition of paracentesis-induced blood-aqueous humor barrier breakdown in cats.
[So] Source:Am J Vet Res;72(6):826-32, 2011 Jun.
[Is] ISSN:1943-5681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare inhibitory effects of topically applied 1% prednisolone acetate suspension, 0.03% flurbiprofen solution, 0.1% dexamethasone suspension, and 0.1% diclofenac solution on paracentesis-induced blood-aqueous barrier breakdown in cats. ANIMALS: 9 healthy cats. PROCEDURES: Paracentesis of the anterior chamber was performed in both eyes of each cat. One eye of each cat was treated with a topically administered anti-inflammatory medication (1% prednisolone [n = 7 cats], 0.03% flurbiprofen [7], 0.1% dexamethasone [9], or 0.1% diclofenac [8]) immediately following paracentesis and at 6, 10, and 24 hours after paracentesis. The contralateral untreated eye served as the control eye. Each cat had a 6-day washout period between experimental drugs. Breakdown of the blood-aqueous barrier was quantified by use of laser flaremetry. RESULTS: Topical administration of 1% prednisolone significantly reduced aqueous humor flare at 4, 8, and 26 hours after paracentesis. Topical administration of 0.1% diclofenac significantly reduced aqueous humor flare at 8 and 26 hours after paracentesis. Topical administration of 0.1% dexamethasone and 0.03% flurbiprofen did not significantly decrease flare at any time point. There were significant differences in intraocular pressures between NSAID-treated eyes and untreated contralateral eyes. CONCLUSIONS AND CLINICAL RELEVANCE: Topical administration of 1% prednisolone and 0.1% diclofenac significantly reduced intraocular inflammation in cats with paracentesis-induced uveitis. Topical administration of 1% prednisolone or 0.1% diclofenac may be appropriate choices when treating cats with anterior uveitis. Topical administration of diclofenac and flurbiprofen should be used with caution in cats with a history of ocular hypertension.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Barreira Hematoaquosa/efeitos dos fármacos
Doenças do Gato/tratamento farmacológico
Diclofenaco/farmacologia
Flurbiprofeno/farmacologia
Pregnadienotrióis/farmacologia
Uveíte Anterior/veterinária
[Mh] Termos MeSH secundário: Animais
Câmara Anterior/efeitos dos fármacos
Humor Aquoso/efeitos dos fármacos
Barreira Hematoaquosa/fisiopatologia
Doenças do Gato/fisiopatologia
Gatos
Feminino
Pressão Intraocular
Masculino
Hipertensão Ocular/tratamento farmacológico
Hipertensão Ocular/veterinária
Paracentese
Uveíte Anterior/tratamento farmacológico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pregnadienetriols); 144O8QL0L1 (Diclofenac); 5GRO578KLP (Flurbiprofen)
[Em] Mês de entrada:1109
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110602
[St] Status:MEDLINE
[do] DOI:10.2460/ajvr.72.6.826


  5 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21277557
[Au] Autor:Rush RB; Goldstein DA; Callanan DG; Meghpara B; Feuer WJ; Davis JL
[Ad] Endereço:Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
[Ti] Título:Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.
[So] Source:Am J Ophthalmol;151(4):630-6, 2011 Apr.
[Is] ISSN:1879-1891
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate outcomes in birdshot chorioretinopathy following intravitreal implantation of a fluocinolone acetonide-containing drug delivery device. DESIGN: Retrospective, multicenter, interventional case study. METHODS: University- and community-based tertiary care. Twenty-two HLA-A29+ birdshot patients (36 eyes) were implanted with a sustained-release corticosteroid device and followed for up to 3 years. Main outcome measures were Snellen acuity, intraocular inflammation, adjunctive therapy, cataract, ocular hypertension, or glaucoma. Paired Wilcoxon statistics were used to analyze visual acuities; paired McNemar statistics were used to analyze presence or absence of other outcomes. RESULTS: Nineteen of 22 patients (32 eyes) completed 12 months of follow-up with improvement in median visual acuity (P=.015). Prior to implantation, 18 of 22 patients (82%) received immunosuppressive therapy versus 1 of 19 (5%) by 12 months (P<.001). Eyes with zero vitreous haze increased from 7 of 27 scored eyes (26%) at baseline to 30 of 30 eyes (100%) by 12 months (P<.001). Cystoid macular edema decreased from 13 of 36 eyes (36%) at baseline to 2 of 32 eyes (6%) at 12 months (P=.006). Five of 24 phakic eyes at baseline exited the study before surgery; all other eyes received cataract surgery. One hundred percent of study eyes had ocular hypertension, required intraocular pressure-lowering therapy, or had glaucoma surgery by 12 months. CONCLUSIONS: Implantation of a fluocinolone acetonide-containing intraocular device in birdshot chorioretinopathy can improve vision, control inflammation, and eliminate systemic therapy. There is a high incidence of cataract progression and intraocular hypertension or glaucoma.
[Mh] Termos MeSH primário: Doenças da Coroide/tratamento farmacológico
Sistemas de Liberação de Medicamentos
Pregnadienotrióis/administração & dosagem
Doenças Retinianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Catarata/fisiopatologia
Doenças da Coroide/fisiopatologia
Implantes de Medicamento
Eletrorretinografia
Feminino
Angiofluoresceinografia
Seres Humanos
Masculino
Meia-Idade
Pregnadienotrióis/efeitos adversos
Doenças Retinianas/fisiopatologia
Estudos Retrospectivos
Resultado do Tratamento
Acuidade Visual/fisiologia
Campos Visuais
Corpo Vítreo
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Drug Implants); 0 (Pregnadienetriols); 3693-39-8 (flucloronide)
[Em] Mês de entrada:1105
[Cu] Atualização por classe:161025
[Lr] Data última revisão:
161025
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:110201
[St] Status:MEDLINE
[do] DOI:10.1016/j.ajo.2010.10.005


  6 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21034309
[Au] Autor:Ramaiya KJ; Rao PK
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Saint Louis, Missouri, USA.
[Ti] Título:Herpetic necrotizing retinitis following flucinolone acetonide intravitreal implant.
[So] Source:Ocul Immunol Inflamm;19(1):72-4, 2011 Feb.
[Is] ISSN:1744-5078
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report a case of herpes simplex virus-induced herpetic necrotizing retinitis after placement of a flucinolone acetonide (Retisert) intravitreal implant. DESIGN: Interventional case report. METHODS: Retrospective chart review. RESULTS: A 22-year-old male with idiopathic unilateral panuveitis since 2002 that was intolerant of systemic immunosuppressive therapy received a flucinolone acetonide implant 6 years later. Intraocular inflammation was completely quiescent until 1 year following the implant, when he developed retinitis. To the authors' knowledge, this is the first reported case of polymerase chain reaction-proven herpetic necrotizing retinitis following implantation of a Retisert device. CONCLUSIONS: Although rare, herpetic necrotizing retinitis can occur in the setting of local ocular immunosuppression with the Retisert intravitreal implant. This potential infection should be considered in the face of recurrent uveitis following Retisert implantation.
[Mh] Termos MeSH primário: Implantes de Medicamento/efeitos adversos
Infecções Oculares Virais/diagnóstico
Herpes Simples/diagnóstico
Herpes Simples/etiologia
Imunossupressores/efeitos adversos
Pan-Uveíte/tratamento farmacológico
Pregnadienotrióis/efeitos adversos
Síndrome de Necrose Retiniana Aguda/diagnóstico
[Mh] Termos MeSH secundário: Aciclovir/análogos & derivados
Aciclovir/uso terapêutico
Antivirais/efeitos adversos
Antivirais/uso terapêutico
Azatioprina/efeitos adversos
Azatioprina/uso terapêutico
Catarata/etiologia
Implantes de Medicamento/uso terapêutico
Infecções Oculares Virais/virologia
Herpes Simples/tratamento farmacológico
Herpesvirus Humano 2/isolamento & purificação
Seres Humanos
Imunossupressores/administração & dosagem
Masculino
Ácido Micofenólico/efeitos adversos
Ácido Micofenólico/análogos & derivados
Ácido Micofenólico/uso terapêutico
Pregnadienotrióis/uso terapêutico
Síndrome de Necrose Retiniana Aguda/virologia
Resultado do Tratamento
Valina/análogos & derivados
Valina/uso terapêutico
Acuidade Visual
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Drug Implants); 0 (Immunosuppressive Agents); 0 (Pregnadienetriols); 3693-39-8 (flucloronide); HG18B9YRS7 (Valine); HU9DX48N0T (Mycophenolic Acid); MRK240IY2L (Azathioprine); MZ1IW7Q79D (valacyclovir); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1104
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101102
[St] Status:MEDLINE
[do] DOI:10.3109/09273948.2010.520404


  7 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20603583
[Au] Autor:Cho AR; Cha YJ; Kim HR; Park EK; Cha EJ
[Ad] Endereço:Department of Laboratory Medicine, Chung-Ang University, Seoul, Korea.
[Ti] Título:[Acquired amegakaryocytic thrombocytopenia after thymectomy in a case of pure red cell aplasia associated with thymoma].
[So] Source:Korean J Lab Med;30(3):244-8, 2010 Jun.
[Is] ISSN:1598-6535
[Cp] País de publicação:Korea (South)
[La] Idioma:kor
[Ab] Resumo:The association of thymoma with pure red cell aplasia has been well documented, but amegakaryocytic thrombocytopenia is not a recognized paraneoplastic syndrome complicating thymoma. We report a case of thymoma-complicated pure red cell aplasia and amegakaryocytic thrombocytopenia in a 73-yr-old woman. Pure red cell aplasia was diagnosed seven months after the detection of thymoma. One year after the diagnosis of pure red cell aplasia and seven months after thymectomy, bone marrow aspiration and biopsy showed an absence of megakaryocytes, marked erythroid hypoplasia with normal myeloid series. A diagnosis of amegakaryocytic thrombocytopenia and pure red cell aplasia was made. Oral steroid maintenance therapy resulted in recovery of platelet count. She has still transfusion-dependent anemia but platelet and neutrophil counts had been maintained in normal range for more than five months, until the last follow-up. We think that autoreactive T cells may induce a clinical autoimmune response even after eradication of thymoma, and aplastic anemia as a late complication following thymectomy was described in previous cases. This patient also has to be under a close observation because of the possibility to evolve into aplastic anemia.
[Mh] Termos MeSH primário: Aplasia Pura de Série Vermelha/diagnóstico
Trombocitopenia/diagnóstico
Trombocitopenia/etiologia
Timectomia/efeitos adversos
Timoma/complicações
Neoplasias do Timo/complicações
[Mh] Termos MeSH secundário: Idoso
Medula Óssea/patologia
Feminino
Seres Humanos
Imidazóis/uso terapêutico
Megacariócitos/patologia
Pregnadienotrióis/uso terapêutico
Aplasia Pura de Série Vermelha/complicações
Trombocitopenia/tratamento farmacológico
Timoma/diagnóstico
Timoma/cirurgia
Neoplasias do Timo/diagnóstico
Neoplasias do Timo/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Imidazoles); 0 (Pregnadienetriols); 45IOG00G0B (prednazoline)
[Em] Mês de entrada:1008
[Cu] Atualização por classe:140530
[Lr] Data última revisão:
140530
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100707
[St] Status:MEDLINE
[do] DOI:10.3343/kjlm.2010.30.3.244


  8 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:20565463
[Au] Autor:Sanmukhani J; Shah V; Baxi S; Tripathi C
[Ti] Título:Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: a case report.
[So] Source:Br J Clin Pharmacol;69(6):703-4, 2010 Jun.
[Is] ISSN:1365-2125
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Antiprotozoários/efeitos adversos
Erupção por Droga/etiologia
Metronidazol/análogos & derivados
Nitroimidazóis/efeitos adversos
Ornidazol/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Antiprotozoários/administração & dosagem
Biópsia
Reações Cruzadas
Erupção por Droga/tratamento farmacológico
Erupção por Droga/patologia
Glucocorticoides/uso terapêutico
Seres Humanos
Masculino
Metronidazol/efeitos adversos
Nitroimidazóis/química
Ornidazol/administração & dosagem
Pregnadienotrióis/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Glucocorticoids); 0 (Nitroimidazoles); 0 (Pregnadienetriols); 140QMO216E (Metronidazole); 3693-39-8 (flucloronide); 62XCK0G93T (Ornidazole); R3459K699K (secnidazole)
[Em] Mês de entrada:1012
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100623
[St] Status:MEDLINE
[do] DOI:10.1111/j.1365-2125.2010.03651.x


  9 / 73 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20376684
[Au] Autor:Kiyokawa K; Kawai S
[Ad] Endereço:The Department of General Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan.
[Ti] Título:Efficacy of steroid therapy on adult patients with severe pneumonia.
[So] Source:J Infect Chemother;16(4):266-71, 2010 Aug.
[Is] ISSN:1437-7780
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Optimal management of steroid therapy for severe pneumonia is an urgent issue. One hundred forty-eight elderly patients enrolled in our study were treated for severe pneumonia in a university hospital in Tokyo from 1998 through 2002. Steroid drugs were given to 82 patients (55.4%), whereas 66 (44.6%) received no steroids. Based on this main division, retrospective analyses were performed with regard to patient characteristics, antimicrobial agents, use or nonuse of mechanical ventilators, and prognoses. Significant difference was not seen in age, sex, underlying disease, isolated pathogens, and artificial respirator between the steroid and nonsteroid groups. Partial pressure of oxygen in arterial blood/fraction of inspired oxygen (Pao(2)/Fio(2)) ratio was significantly lower in the steroid (227.2 +/- 96.9) compared with the nonsteroid group (271.6 +/- 86.4) (P < 0.01). Prognoses were evaluated 21 days after treatment initiation. Significant differences appeared: First, the average cure rate of patients who took steroids within 3 days after starting treatment was 62.7%, whereas the rate was 12.9% (P < 0.001) in those who did not take steroids earlier than the 4th day. The cure rate of the nonsteroid group was 39.3% (P < 0.001). Second, the total dose of steroids (methylprednisolone) given within 7 days was less in cured cases (774 +/- 749 mg) than in noncured cases (1,190 +/- 768 mg) (P < 0.05). In conclusion, steroids should be administered in the early stage after onset of pneumonia, and large doses of steroids becomes a compounding factor in the prognosis of pneumonia.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Pneumonia/tratamento farmacológico
Pregnadienotrióis/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Distribuição de Qui-Quadrado
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Meia-Idade
Pneumonia/diagnóstico
Prognóstico
Respiração Artificial
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pregnadienetriols)
[Em] Mês de entrada:1012
[Cu] Atualização por classe:100805
[Lr] Data última revisão:
100805
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100409
[St] Status:MEDLINE
[do] DOI:10.1007/s10156-010-0049-5


  10 / 73 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:19028513
[Au] Autor:Zmijewski MA; Li W; Zjawiony JK; Sweatman TW; Chen J; Miller DD; Slominski AT
[Ad] Endereço:Department of Pathology and Laboratory Medicine, Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
[Ti] Título:Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells.
[So] Source:Steroids;74(2):218-28, 2009 Feb.
[Is] ISSN:0039-128X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pregna-5,7-dienes and their hydroxylated derivatives can be formed in vivo when there is a deficiency in 7-dehydrocholesterol (7-DHC) Delta-reductase function, e.g., Smith-Lemli-Opitz syndrome (SLOS). Ultraviolet B (UVB) radiation induces photoconversion of 7-DHC to vitamin D3, lumisterol3 and tachysterol3. Two epimers (20R and 20S) of pregna-5,7-diene-3beta,17alpha,20-triol (4R and 4S, respectively) were synthesized and their UVB photo-conversion products identified as corresponding 9,10-secosteroids with vitamin D-like and tachysterol-like structures, and 5,7-dienes with inverted configuration at C-9 and C-10 (lumisterol-like). The number and character of the products and the dynamics of the process were dependent on the UVB dose. At high UVB doses, the formation of multiple oxidized derivatives of the primary products, and the formation of 5,7,9(11)-triene, were observed. The production of vitamin D-like, tachysterol-like and lumisterol-like derivatives was also observed in human skin treated with 4R and 4S, and subjected to UV irradiation, as shown by RP-HPLC. Newly synthesized compounds inhibited melanoma growth in dose dependent manner, and some of them showed equal or higher potency than 1,25(OH)2D3. In summary, we have characterized for the first time the products of UV induced conversion of pregna-5,7-diene-3beta,17alpha,20-triols and documented that the newly synthesized compounds have antiproliferative properties against melanoma cells.
[Mh] Termos MeSH primário: Melanoma/metabolismo
Melanoma/patologia
Fotólise/efeitos da radiação
Pregnadienos/química
Pregnadienos/farmacologia
Pregnadienotrióis/química
Pregnadienotrióis/síntese química
Pregnadienotrióis/farmacologia
[Mh] Termos MeSH secundário: Acetilação
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Seres Humanos
Espectroscopia de Ressonância Magnética
Espectrometria de Massas
Pregnadienos/síntese química
Pregnadienos/metabolismo
Pregnadienotrióis/metabolismo
Secoesteroides/análise
Secoesteroides/química
Pele/metabolismo
Pele/efeitos da radiação
Estereoisomerismo
Raios Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Pregnadienes); 0 (Pregnadienetriols); 0 (Secosteroids)
[Em] Mês de entrada:0904
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:081126
[St] Status:MEDLINE
[do] DOI:10.1016/j.steroids.2008.10.017



página 1 de 8 ir para página                    
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde